Last reviewed · How we verify

NCT07494578: FLOWER

Observational Study Regarding the Combination of Fluoropyrimidine and Bevacizumab in Patients With mCRC

Active, enrolled Last updated 27 March 2026
What this trial tests

trial testing Fluoropyrimidine in Colon Cancer Metastatic in 300 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
1 July 2025
Primary endpoint
1 July 2027
1 August 2027

Quick facts

Lead sponsorFondazione Policlinico Universitario Agostino Gemelli IRCCS
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment300
Start date1 July 2025
Primary completion1 July 2027
Estimated completion1 August 2027
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Who can join

18 and older, any sex, with Colon Cancer Metastatic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will enroll patients with metastatic colorectal cancer treated with the combination of Trifluridine/Tipiracile and Bevacizumab across 15 italian centers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Fluoropyrimidine

Trials testing the same drug.

Other recruiting trials for Colon Cancer Metastatic

Currently open trials in the same condition.

Other Fondazione Policlinico Universitario Agostino Gemelli IRCCS trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07494578.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing